Crossmark

Efficacy and Safety of Insulin Glargine 300 U/mL in People with Type 2 Diabetes Uncontrolled on Basal Insulin: The 26-Week Interventional, Single-Arm ARTEMIS-DM Study

Crossref DOI link: https://doi.org/10.1007/s13300-022-01271-7

Published Online: 2022-06-17

Published Print: 2022-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sethi, Bipin

Al-Rubeaan, Khalid

Unubol, Mustafa

Mabunay, Maria A.

Berthou, Baptiste

Pilorget, Valerie

Vethakkan, Shireene R.

Frechtel, Gustavo
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct03760991 at ClinicalTrials.gov

Documents that mention this clinical trial

Efficacy and Safety of Insulin Glargine 300 U/mL in People with Type 2 Diabetes Uncontrolled on Basal Insulin: The 26-Week Interventional, Single-Arm ARTEMIS-DM Study
https://doi.org/10.1007/s13300-022-01271-7
Funding

Funding for this research was provided by:

Sanofi
License Information

Text and Data Mining valid from 2022-06-17

Version of Record valid from 2022-06-17
More Information

Article History

Received: 5 March 2022

Accepted: 9 May 2022

First Online: 17 June 2022

Document is current

Any future updates will be listed below